Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F20%3A00072875" target="_blank" >RIV/00159816:_____/20:00072875 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/20:00116192 RIV/65269705:_____/20:00072875 RIV/00209805:_____/20:00078408
Result on the web
<a href="https://www.frontiersin.org/articles/10.3389/fonc.2020.00840/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fonc.2020.00840/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fonc.2020.00840" target="_blank" >10.3389/fonc.2020.00840</a>
Alternative languages
Result language
angličtina
Original language name
Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade
Original language description
The aim of this retrospective study is to provide real-world evidence in glioblastoma treatment and to compare overall survival after Stupp's regimen treatment today and a decade ago. A current consecutive cohort of histologically confirmed glioblastoma irradiated from 1/2014 to 12/2017 in our cancer center was compared with an already published historical control of patients treated in 1/2003-12/2009. A total of new 155 patients was analyzed, median age 60.9 years, 61% men, 58 patients (37%) underwent gross total tumor resection. Stupp's regimen was indicated in 90 patients (58%), 65 patients (42%) underwent radiotherapy alone. Median progression-free survival in Stupp's regimen cohort was 6.7 months, median OS 16.0 months, and 2-year OS 30.7%. OS was longer if patients were able to finish at least three cycles of adjuvant chemotherapy (median 23.3 months and 43.9% of patients lived at 2 years after surgery). Rapid early progression prior to radiotherapy was a negative prognostic factor with HR 1.87 (p = 0.007). The interval between surgery and the start of radiotherapy (median 6.7 weeks) was not prognostically significant (p = 0.825). The median OS in the current cohort was about 2 months longer than in the historical control group treated 10 years ago (16 vs. 13.8 months) using the same Stupp's regimen. Taking into account differences in patient's characteristics between current and historical cohorts, age, extent of resection, and ECOG patient performance status adjusted HR (Stupp's regimen vs. RT alone) for OS was determined as 0.45 (p = 0.002).
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
<a href="/en/project/NU20-03-00148" target="_blank" >NU20-03-00148: Diagnosis and management of glioblastoma patients with rapid early progression before the initiation of adjuvant oncology treatment</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in Oncology
ISSN
2234-943X
e-ISSN
—
Volume of the periodical
10
Issue of the periodical within the volume
3 JULY
Country of publishing house
CH - SWITZERLAND
Number of pages
11
Pages from-to
840
UT code for WoS article
000553991600001
EID of the result in the Scopus database
2-s2.0-85088464842